Soligenix

Operates through Specialized BioTherapeutics, which develops orphan-disease candidates, and Public Health Solutions, which pursues heat-stable biodefense vaccines and infectious-disease therapeutics. Its active clinical focus is dusquetide for Behçet's disease; a visible-light-activated synthetic-hypericin gel remains in development for psoriasis. An oral-mucositis program requires a partner and another late-stage trial.

Uses orphan-disease development expertise, in-licensed technology and partners or out-licenses to take programs forward, directly managing clinical studies while outsourcing parts of development and manufacturing. Work spans the United States, Europe and the United Kingdom, including public-health efforts tied to U.S. agencies and university research. No products are approved or sold.

ThermoVax provides a heat-stabilization platform for subunit vaccines, including ricin and filovirus candidates. RiVax's regulatory path depends on the FDA Animal Rule and validated immune correlates, and Public Health Solutions development is contingent on continued government grants, contracts or other support.